Following Rova-T Failure, AbbVie Enters Immuno-Oncology Deal with Idera

Following Rova-T Failure, AbbVie Enters Immuno-Oncology Deal with Idera

New Tools to the 4 Pillars of Cancer Treatment: Biomarker Testing and Chronic Cancers

New Tools to the 4 Pillars of Cancer Treatment: Biomarker Testing and Chronic Cancers

Top 10 Immuno-Oncology Startups

Top 10 Immuno-Oncology Startups

Tumor Microenvironments Are Target-Rich Environments

Tumor Microenvironments Are Target-Rich Environments

Big Keytruda survival win sets Merck up to steal Bristol-Myers Squibb’s kidney cancer share

Big Keytruda survival win sets Merck up to steal Bristol-Myers Squibb's kidney cancer share

Celgene Strikes Deal Worth Nearly $1 Billion for Blood Cancer Treatment

Celgene Strikes Deal Worth Nearly $1 Billion for Blood Cancer Treatment